Drug Information
| General Information | ||||||
|---|---|---|---|---|---|---|
| Drug ID |
DR00174
|
|||||
| Drug Name |
Tenofovir
|
|||||
| Synonyms |
(R)-9-(2-Phosphonomethoxypropyl)adenine; (R)-9-(2-Phosphonylmethoxypropyl)adenine; (R)-PMPA; Apropovir; D,L-Tenofovir; GNA & Tenofovir; GS 1275; GS 1278; GS1278; HHA & Tenofovir; KS-5021; PMPA; PMPA-(R); Phosphonic acid, [[(1R)-2-(6-amino-9H-purin-9-yl)-1-methylethoxy]methyl]-& Galanthus nivalis agglutinin (GNA); Phosphonic acid, [[(1R)-2-(6-amino-9H-purin-9-yl)-1-methylethoxy]methyl]-& Hippeastrum hybrid agglutinin(HHA); Phosphonic acid, [[(1R)-2-(6-amino-9H-purin-9-yl)-1-methylethoxy]methyl]-(9CI); Phosphonic acid, [[2-(6-amino-9H-purin-9; TDF; TFV; Tenefovir; Viread (TN); Viread, Tenofovir; [(2R)-1-(6-aminopurin-9-yl)propan-2-yl]oxymethylphosphonic acid
|
|||||
| Drug Type |
Small molecular drug
|
|||||
| Indication | Human immunodeficiency virus infection [ICD11: 1C62.Z] | Approved | [1] | |||
| Therapeutic Class |
Anti-HIV Agents
|
|||||
| Structure |
|
 |
||||
| 3D MOL | 2D MOL | |||||
| Formula |
C9H14N5O4P
|
|||||
| Canonical SMILES |
CC(CN1C=NC2=C(N=CN=C21)N)OCP(=O)(O)O
|
|||||
| InChI |
InChI=1S/C9H14N5O4P/c1-6(18-5-19(15,16)17)2-14-4-13-7-8(10)11-3-12-9(7)14/h3-4,6H,2,5H2,1H3,(H2,10,11,12)(H2,15,16,17)/t6-/m1/s1
|
|||||
| InChIKey |
SGOIRFVFHAKUTI-ZCFIWIBFSA-N
|
|||||
| CAS Number |
CAS 147127-20-6
|
|||||
| Pharmaceutical Properties | Molecular Weight | 287.21 | Topological Polar Surface Area | 136 | ||
| Heavy Atom Count | 19 | Rotatable Bond Count | 5 | |||
| Hydrogen Bond Donor Count | 3 | Hydrogen Bond Acceptor Count | 8 | |||
| XLogP |
-1.6
|
|||||
| PubChem CID | ||||||
| PubChem SID |
102979961
, 10304546
, 103169192
, 109738216
, 12014981
, 121362228
, 124757224
, 125164028
, 126610616
, 126628295
, 126655803
, 127310209
, 127310210
, 127339001
, 127339002
, 129233080
, 134337989
, 135078595
, 135606020
, 135611180
, 135682533
, 135698226
, 136367764
, 136372374
, 136905481
, 137005935
, 141613622
, 14873257
, 151996120
, 152034360
, 152165365
, 152246774
, 152344570
, 160963648
, 162184452
, 162793588
, 163658367
, 163813066
, 171563543
, 3727050
, 3727057
, 46508131
, 48424314
, 50112788
, 50437671
, 57405565
, 610434
, 7980754
, 92719253
, 99437132
|
|||||
| ChEBI ID |
CHEBI:63625
|
|||||
| TTD Drug ID | ||||||
| DT(s) Transporting This Drug | BCRP | Transporter Info | Breast cancer resistance protein | Substrate | [2] | |
| MRP4 | Transporter Info | Multidrug resistance-associated protein 4 | Substrate | [3] | ||
| MRP7 | Transporter Info | Multidrug resistance-associated protein 7 | Substrate | [4] | ||
| MRP8 | Transporter Info | Multidrug resistance-associated protein 8 | Substrate | [5] | ||
| OAT1 | Transporter Info | Organic anion transporter 1 | Substrate | [6] | ||
| OAT3 | Transporter Info | Organic anion transporter 3 | Substrate | [7] | ||
| P-GP | Transporter Info | P-glycoprotein 1 | Substrate | [8] | ||
| Drug-Transporter Activity Data | ||||||
| Drug-Transporter Activity Data | OAT1 | Transporter Info | Km = 33.8 microM | Chinese hamster ovary (CHO) cells-OAT1 | [6] | |
| OAT3 | Transporter Info | Km = 770 microM | BHK-21 cells-OAT3 | [9] | ||
| References | ||||||
| 1 | Tenofovir was approved by FDA. The official website of the U.S. Food and Drug Administration. (2019) | |||||
| 2 | KEGG: new perspectives on genomes, pathways, diseases and drugs. Nucleic Acids Res. 2017 Jan 4;45(D1):D353-D361. (dg:DG01913) | |||||
| 3 | Functional involvement of multidrug resistance-associated protein 4 (MRP4/ABCC4) in the renal elimination of the antiviral drugs adefovir and tenofovir. Mol Pharmacol. 2007 Feb;71(2):619-27. | |||||
| 4 | Genetic variants of ABCC10, a novel tenofovir transporter, are associated with kidney tubular dysfunction. J Infect Dis. 2011 Jul 1;204(1):145-53. | |||||
| 5 | Tenofovir Disoproxil Fumarate Is a New Substrate of ATP-Binding Cassette Subfamily C Member 11. Antimicrob Agents Chemother. 2017 Mar 24;61(4). pii: e01725-16. | |||||
| 6 | Human renal organic anion transporter 1 (hOAT1) and its role in the nephrotoxicity of antiviral nucleotide analogs. Nucleosides Nucleotides Nucleic Acids. 2001 Apr-Jul;20(4-7):641-8. | |||||
| 7 | Tenofovir alafenamide is not a substrate for renal organic anion transporters (OATs) and does not exhibit OAT-dependent cytotoxicity. Antivir Ther. 2014;19(7):687-92. | |||||
| 8 | KEGG: new perspectives on genomes, pathways, diseases and drugs. Nucleic Acids Res. 2017 Jan 4;45(D1):D353-D361. (dg:DG01665) | |||||
| 9 | Novel nucleotide human immunodeficiency virus reverse transcriptase inhibitor GS-9148 with a low nephrotoxic potential: characterization of renal transport and accumulation. Antimicrob Agents Chemother. 2009 Jan;53(1):150-6. | |||||
If you find any error in data or bug in web service, please kindly report it to Dr. Yin and Dr. Li.